Title: Targeting the BAF57 SWI/SNF subunit in prostate cancer: A novel platform to control androgen receptor activity
Authors: Link, Kevin A ×
Balasubramaniam, Sucharitha
Sharma, Ankur
Comstock, Clay E. S
Godoy-Tundidor, Sonia
Powers, Nathan
Cao, Khanh H
Haelens, Anna
Claessens, Frank
Revelo, Monica P
Knudsen, Karen E #
Issue Date: Jun-2008
Publisher: Amer assoc cancer research
Series Title: Cancer Research vol:68 issue:12 pages:4551-4558
Abstract: The androgen receptor (AIR) is critical for disseminated prostate cancer proliferation and survival. AR activity is targeted either through prevention of ligand synthesis or through the use of antagonists that bind the COOH-terminal ligand-binding domain. Although initially effective, treatment fails due to restored AR activity in the presence of therapeutics. Thus, new means must be developed to target AR activity. The SWI/SNF chromatin remodeling complex is critical for AR transcriptional activity, and the BAF57 SWI/SNF subunit facilitates direct interaction with the receptor. Although selected SWI/SNF subunit expression is reduced in prostate cancer, we show that BAF57 is retained in human disease and is elevated in a subset of tumors. Functional analyses showed that BAF57 contributes uniquely to androgen-mediated stimulation of transcription without compromising the effectiveness of AR antagonists. Subsequent studies revealed that BAF57 is recruited to the AR DNA-binding domain/hinge region, which occurs concomitant with receptor activation. These data provided the basis for a novel inhibitor derived from BAF57 [BAF57 inhibitory peptide (BIPep)], which blocked AR residence on chromatin and resultant AR-dependent gene activation. Importantly, BIPep expression was sufficient to inhibit androgen-dependent prostate cancer cell proliferation in AR-positive cells. In summary, these data identify blockade of AR-BAF57 interaction as a novel means to target agonist-induced AIR function in prostate cancer, and provide the first evidence that abrogation of SWI/SNF function can he developed as a point of therapeutic intervention in prostate cancer.
ISSN: 0008-5472
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Molecular Endocrinology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science